लोड हो रहा है...
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval
Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD2...
में बचाया:
| में प्रकाशित: | Blood Adv |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
American Society of Hematology
2019
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784515/ https://ncbi.nlm.nih.gov/pubmed/31594764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000507 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|